A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors

Background We conducted a first-in-Japanese, phase I study of ontuxizumab, a humanized, anti-endosialin monoclonal antibody, to confirm its tolerability, safety, and pharmacokinetics, and identify exploratory efficacy. Methods This was a multicenter, multiple-dose, open-label study in Japanese patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Doi, Toshihiko, Aramaki, Takeshi, Yasui, Hirofumi, Muro, Kei, Ikeda, Masafumi, Okusaka, Takuji, Inaba, Yoshitaka, Nakai, Kenya, Ikezawa, Hiroki, Nakajima, Ryo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736902/
https://www.ncbi.nlm.nih.gov/pubmed/30623276
http://dx.doi.org/10.1007/s10637-018-0713-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736902/
https://www.ncbi.nlm.nih.gov/pubmed/30623276
http://dx.doi.org/10.1007/s10637-018-0713-7

Ejemplares similares